Abstract
Defining the study population is an integral part of posing the primary question. It is not enough to claim that an intervention is or is not effective without describing the type of participant on which the intervention was tested. The description requires specification of criteria for eligibility. This chapter focuses on how to define the study population. In addition, it considers two questions. First, to what extent will the results of the trial be generalizable to a broader population? Second, what impact does selection of eligibility criteria have on participant recruitment, or, more generally, study feasibility? This issue is also discussed in Chap. 10.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
CONSORT. http://www.consort-statement.org
Van Spall HGC, Toren A, Kiss A, Fowler RA. Eligibility criteria of randomized controlled trials published in high-impact general medical journals: a systematic sampling review. JAMA 2007;297:1233–1240.
Diabetic Retinopathy Study Research Group. Preliminary report on effects of photocoagulation therapy. Am J Ophthalmol 1976;81:383–396.
Diabetic Retinopathy Study Research Group. Photocoagulation treatment of proliferative diabetic retinopathy: the second report of diabetic retinopathy study findings. Ophthalmology 1978;85:82–106.
Fraser DW, Tsai TR, Orenstein W, et al. Legionnaires’ Disease: description of an epidemic of pneumonia. N Engl J Med 1977;297:1189–1197.
Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension: results in patients with diastolic blood pressures averaging 115 through 129 mm Hg. JAMA 1967;202:1028–1034.
Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension: II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA 1970;213:1143–1152.
Hypertension Detection and Follow-up Program Cooperative Group. Five-year findings of the hypertension detection and follow-up program. 1. Reduction in mortality of persons with high blood pressure, including mild hypertension. JAMA 1979;242:2562–2571.
Ridker PM, Danielson E, Fonseca FAH, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195–2207.
Sondik EJ, Brown BW, Jr., Silvers A. High risk subjects and the cost of large field trials. J Chronic Dis 1974;27:177–187.
Tunis SR, Stryer DB, Clancy CM. Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy. JAMA 2003;290:1624–1632.
Douglas PS. Gender, cardiology, and optimal medical care. Circulation 1986;74:917–919.
Bennett JC, for the Board on Health Sciences Policy of the Institute of Medicine. Inclusion of women in clinical trials – policies for population subgroups. N Engl J Med 1993;329:288–292.
Freedman LS, Simon R, Foulkes MA, et al. Inclusion of women and minorities in clinical trials and the NIH Revitalization Act of 1993 – the perspective of NIH clinical trialists. Control Clin Trials 1995;16:277–285.
NIH Policy and Guidelines on the Inclusion of Women and Minorities as Subjects in Clinical Research – Amended, October, 2001. http://grants.nih.gov/grants/funding/women_min/guidelines_amended_10_2001.htm
Horwitz O, Wilbek E. Effect of tuberculosis infection on mortality risk. Am Rev Respir Dis 1971;104:643–655.
Wilhelmsen L, Ljungberg S, Wedel H, Werko L. A comparison between participants and non-participants in a primary preventive trial. J Chronic Dis 1976;29:331–339.
Smith P, Arnesen H. Mortality in non-consenters in a post-myocardial infarction trial. J Intern Med 1990;228:253–256.
Pedersen TR. The Norwegian Multicenter Study of timolol after myocardial infarction. Circulation 1983;67(suppl 1):I-49–I-53.
CASS Principal Investigators and Their Associates. Coronary Artery Surgery Study (CASS): a randomized trial of coronary artery bypass surgery. Comparability of entry characteristics and survival in randomized patients and nonrandomized patients meeting randomization criteria. J Am Coll Cardiol 1984;3:114–128.
Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised clinical trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71–86; correction BMJ 2002;324:141.
Steering Committee of the Physicians’ Health Study Research Group. Final report on the aspirin component of the ongoing Physicians’ Health Study. N Engl J Med 1989;321:129–135.
Peto R, Gray R, Collins R, et al. Randomized trial of prophylactic daily aspirin in British male doctors. Br Med J 1988;296:313–316.
Ridker PM, Cook NR, Lee I-M, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005;352:1293–1304.
Berger JS, Roncaglioni MC, Avanzini F, et al. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA 2006;295:306–313; correction JAMA 2006;295:2002.
Benedict GW. LRC Coronary Prevention Trial: Baltimore. Clin Pharmacol Ther 1979;25:685–687.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Copyright information
© 2010 Springer New York
About this chapter
Cite this chapter
Friedman, L.M., Furberg, C.D., DeMets, D.L. (2010). Study Population. In: Fundamentals of Clinical Trials. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-1586-3_4
Download citation
DOI: https://doi.org/10.1007/978-1-4419-1586-3_4
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4419-1585-6
Online ISBN: 978-1-4419-1586-3
eBook Packages: Mathematics and StatisticsMathematics and Statistics (R0)